Wednesday, January 9, 2013

Dr. Reddy’s in Patent Suit over Vimovo

Plaintiffs: AstraZeneca AB, AstraZeneca LP, KBI-E and Pozen 

Defendants: Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd

Case Number: 3:13-cv-00091

Date Filed: January 04, 2013

Court: New Jersey District Court

Patents-in-Suit: US5714504, US6369085, US7411070, US6926907 and US7745466

Patent Number
Current Assignee[*]
Issued Date
Expiration Date[†]
Case Type

Feb 03, 1998
Feb 03, 2015

Apr 09, 2002
May 30, 2017
Form of S-omeprazole
AstraZeneca AB (as per face page)
Aug 12, 2008
May 30, 2017
Form of S-omeprazole

Aug 09, 2005
May 31, 2022
Pharmaceutical compositions for the coordinated delivery of NSAIDs
AstraZeneca AB
(as per face page)
Jun 29, 2010
May 30, 2017
Declaratory Judgment
Form of S-omeprazole
Table information sourced from Maxval’s Assignment Database

KBI-E is exclusive licensee of the ’466, ‘070, ‘085 and ‘504 patents.

About the Parties:
AstraZeneca AB manufactures and distributes pharmaceutical products. It also undertakes research and development activities. The company was founded in 1913 and formerly known as Astra AB. AstraZeneca AB operates as a subsidiary of AstraZeneca plc.

AstraZeneca LP is a pharmaceutical company engaged in discovering, developing, producing, and marketing medications. It offers gastrointestinal, cardiovascular/metabolic, neuroscience, mental illness, respiratory, oncology, and infectious disease medicines. The company was founded in 1912 and operates as a subsidiary of AstraZeneca plc.

Pozen is a pharmaceutical company that develops products for the treatment of acute and chronic pain and other pain-related conditions in the United States. Its products include Treximet and VIMOVO. It has collaborations with AstraZeneca AB for the development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with the NSAID naproxen. 

Dr. Reddy’s Laboratories (DRL) is an integrated pharmaceutical company focused on providing medicines through its three business segments: Global Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment and Proprietary Products segment. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. 

As in Complaint:
AstraZeneca LP is the current holder[‡] of New Drug Application (NDA) no. 022511 for Vimovo® delayed release tablets (source: Maxval’s Patent Marker) that is approved by FDA. Vimovo (see Fig. 1) contains a combination of esomeprazole and naproxen. It works by reducing substances in the body that cause inflammation, pain, and fever and decreases the amount of acid produced in the stomach. Plaintiffs allege that DRL seeks FDA approval to market a generic version of Vimovo® delayed release tablets with the Abbreviated New Drug Application (ANDA) no. 204206 that infringes the above patents.

Other Cases Filed:
Plaintiffs and Defendants have together or individually filled cases against each other. Cases highlighted in complaint are follows:

Case Number
Date Filed
AstraZeneca AB
Dr. Reddy’s Labs Inc.
Apr 21, 2011
AstraZeneca AB
Dr. Reddy’s Labs, Ltd and Dr. Reddy’s Labs, Inc.
Jan 17, 2008
AstraZeneca UK and AstraZeneca LP
Dr. Reddy’s Labs, Ltd and Dr. Reddy’s
Labs, Inc.
Jun 27, 2008
Dr. Reddy’s Labs Ltd and Dr. Reddy’s Labs Inc.
AstraZeneca AB
May 19, 2008
If you are interested in knowing more about the cases filed, please contact us
To get alerts on cases filed, subscribe to our Litigation Alerts.

[*] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.
[†] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
[‡] Patent Marker provides an online environment for patentees to virtually mark products and search for patent related information.

No comments:

Post a Comment